FNDC5 and osteosarcoma: The in vivo studies that assessed irisin levels in healthy and diseased patients show that irisin significantly decreases in patients with prostate [24], osteosarcoma [25], bladder [28], breast [33], colorectal [40], liver [38], and gastric cancers [35].